glucocorticoid receptor agonist-1

Glucocorticoid receptor agonist-1, a potent glucocorticoid receptor agonist, has an IC50 of 2.8 nM[1].

Glucocorticoid receptor agonist-1 Ala-Ala-Mal (compound 88), a glucocorticosteroid and glucocorticoid receptor agonist, can be conjugated with Adalimumab to formulate an ADC [1].

Glucocorticoid Receptor Agonist-1 Phosphate Ala-Ala-Mal functions as a glucocorticoid receptor agonist, utilized in the formulation of anti-CD40 antibody agent conjugates (ADC). It serves as a research tool for exploring inflammation and immune regulation [1].

Glucocorticoid Receptor Agonist-1 Phosphate Ala-Ala-Br is a drug-linker conjugate for antibody-drug conjugates (ADCs), serving as a reaction reagent in the creation of anti-CD40 antibody agent conjugates [1].

Glucocorticoid Receptor Agonist-1 Phosphate (Gly-Glu-Br) is an antibody-drug conjugate (ADC) linker utilized in the synthesis of ABBV-154, ABBV-927, ABBV-368, and related analogs [1].

Glucocorticoid Receptor Agonist-1 Phosphate Gly-Glu (TFA) serves as a cleavable linker for the synthesis of Antibody-Drug Conjugates (ADCs).

Compound 9E, a Glucocorticoid receptor agonist-1-Gly-Glu-Gly, serves as a steroid-linker conjugate designed for the synthesis of Antibody-Drug Conjugates (ADCs) [1].

Glucocorticoid receptor agonist-1 phosphate Gly-Glu-Mal functions as a glucocorticoid receptor agonist and serves as a drug-linker conjugate for ADC. This compound is instrumental in the synthesis of anti-CD40 antibody agent conjugates (WO2019106608A1; example 9) [1].

AZD2906, a selective glucocorticoid receptor (GR) agonist, demonstrates inhibitory concentrations (IC50s) of 2.2 nM in human GR, 0.3 nM in rat peripheral blood mononuclear cells (PBMC), 41.6 nM in human whole blood, and 7.5 nM in rat whole blood, respectively[1]. Additionally, it induces an increase in micronucleated immature erythrocytes within rat bone marrow.

Fluocinolone acetonide 3-benzylaniline (Precursor Example 1) is a conjugate of a glucocorticoid receptor agonist and a linker, utilized in the synthesis of anti-CD40 antibody-drug conjugates (ADCs).

Glucocorticoids receptor agonist 1 (GRA-1) is a highly effective arylpyrazole-based compound that acts as an agonist for the glucocorticoid receptor. GRA-1 exhibits strong anti-inflammatory properties while maintaining insulin secretion function.

Glucocorticoid receptor agonist-2 (compound 21), a glucocorticoid receptor agonist with an IC50 value of 6.6 nM, serves as an active reference for ABBV-3373 [1] and is instrumental in the synthesis of anti-inflammatory ADC molecules.

PPARγ GR Modulator 1, an orally active dual agonist for the Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) and Glucocorticoid Receptor (GR), exhibits Ki values of 3.3 and 33.6 μM, respectively. This compound is utilized in metabolic disease research, including diabetes [1].

Glucocorticoid receptor agonist-2 Ala-Ala-Mal (compound 79) serves as a precursor for synthesizing anti-inflammatory antibody-drug conjugate (ADC) molecules and acts as an active reference for ABBV-3373 [1].

Glucocorticoid Receptor Agonist-3 (Preparation 6) acts as a glucocorticoid receptor agonist [1].

Glucocorticoid Receptor Agonist-4 (Compound Preparation 5) serves as an agonist for glucocorticoid receptors and can be conjugated with TNF-α antibodies, facilitating research into autoimmune and inflammatory diseases [1].

Glucocorticoid Receptor Agonist-3 Ala-Ala-Mal (Compound Preparation 8) is a conjugate of an anti-human TNFα antibody and a glucocorticoid receptor agonist (GC). It is utilized in researching autoimmune and inflammatory diseases [1].

Glucocorticoid Receptor Agonist-4 Ala-Ala-Mal (Compound Preparation 9) is a conjugate of anti-human TNFα antibody and glucocorticoid receptor agonist (GC). It is applicable in the research of autoimmune and inflammatory diseases [1].